All lobbying filings

TIBER CREEK GROUP

Lobbying for MERCK & CO., INC · Prescription medicines, vaccines, and biologic therapies

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to immunization policy.

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.

Bills named in this filing 4

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 8857
Next GEN Act of 2026
H.R. 10628
Biosimilars Access and Affordability Act
S. 5571
Biosimilars Access and Affordability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.